Home » Stocks » GRTS

Gritstone Oncology, Inc. (GRTS)

Stock Price: $25.34 USD 3.07 (13.79%)
Updated Jan 20, 2021 1:57 PM EST - Market open
Market Cap 1.05B
Revenue (ttm) 3.57M
Net Income (ttm) -105.85M
Shares Out 37.75M
EPS (ttm) -2.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $25.34
Previous Close $22.27
Change ($) 3.07
Change (%) 13.79%
Day's Open 19.32
Day's Range 18.92 - 35.20
Day's Volume 37,453,274
52-Week Range 2.57 - 35.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 hours ago

Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.

GlobeNewsWire - 6 hours ago

— Deal provides nonexclusive access to Genevant's leading LNP technology for use in Gritstone's self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to i...

Benzinga - 1 day ago

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...

Other stocks mentioned: ACRS, CYAD, MRUS, NERV, TENX
The Motley Fool - 1 day ago

Gritstone's COVID-19 vaccine may have a critical role to play in halting the ongoing pandemic.

GlobeNewsWire - 1 day ago

--Gritstone to Host Conference Call Today at 8:00 a.m. ET-- EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology compan...

GlobeNewsWire - 3 weeks ago

--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing-- --Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) --...

GlobeNewsWire - 4 weeks ago

EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies t...

GuruFocus - 1 month ago

Shareholders of 36KR Holdings Inc (NASDAQ:KRKR) and Gritstone Oncology Inc (NASDAQ:GRTS) have seen their holdings tumble more than 59% over the past 12 months, but analysts still recommend to ...

Other stocks mentioned: KRKR
GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies t...

GlobeNewsWire - 2 months ago

-- The Phase 1 portion s of the stud ies are closed for enrollment ; patient trea tment and follow -up for efficacy and safety continues -- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology , Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunothera...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapie...

Seeking Alpha - 4 months ago

It's Time To Buy Gritstone Oncology As First Vaccine Treated Colorectal Cancer Patient Nears RECIST Confirmed Response

Zacks Investment Research - 5 months ago

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 10.39% and -59.33%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies...

Zacks Investment Research - 5 months ago

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to ...

Seeking Alpha - 5 months ago

Despite The Fall Gritstone Oncology Phase 1 Results Reveal The Efficacy Signal I've Been Looking For

24/7 Wall Street - 6 months ago

For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.

Other stocks mentioned: AZN, IBB, NVAX, REGN, SNY
Forbes - 7 months ago

If there’s one thing that's been made more clear, it’s that the stock market and economy are not reflections of each other. An overbought stock market will eventually turn to the downside, and...

Other stocks mentioned: AGEN, BLNK, MNKD, OCGN
GlobeNewsWire - 7 months ago

EMERYVILLE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies...

Zacks Investment Research - 7 months ago

Gritstone Oncology (GRTS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Gritstone Oncology Inc (GRTS) delivered earnings and revenue surprises of 14.46% and 5.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 8 months ago

EMERYVILLE, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies ...

Zacks Investment Research - 10 months ago

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 1 year ago

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019.

Zacks Investment Research - 1 year ago

Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 1 year ago

-Poster Presentation at SITC 2019 Annual Meeting-

GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies...

GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...

GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapie...

The Motley Fool - 1 year ago

The pricing of a secondary stock offering is taking a toll on the biotech stock.

About GRTS

Gritstone Oncology, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, incl... [Read more...]

Industry
Biotechnology
IPO Date
Sep 28, 2018
CEO
Andrew Allen
Employees
177
Stock Exchange
NASDAQ
Ticker Symbol
GRTS
Full Company Profile

Financial Performance

In 2019, GRTS's revenue was $4.37 million, an increase of 267.73% compared to the previous year's $1.19 million. Losses were -$94.43 million, 45.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for GRTS stock is "Buy." The 12-month stock price forecast is 11.25, which is a decrease of -55.60% from the latest price.

Price Target
$11.25
(-55.60% downside)
Analyst Consensus: Buy